
Quarterly report 2023-Q3
added 11-13-2023
Sientra EBITDA 2011-2026 | SIEN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Sientra
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -42 M | -58 M | -86.3 M | -76.5 M | -59.9 M | -38.9 M | -23.9 M | -5.51 M | -17.9 M | -23.1 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.51 M | -86.3 M | -43.2 M |
Quarterly EBITDA Sientra
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.5 M | -6.21 M | - | - | -12 M | -15.2 M | -14.4 M | - | -8.54 M | -7.05 M | -10.7 M | - | -7.14 M | -8.04 M | -25.8 M | - | -18.9 M | -35.2 M | -25 M | - | -17.1 M | -15.2 M | -18 M | - | -11.8 M | -19.1 M | -10.8 M | - | -9.04 M | -9.78 M | -11.8 M | - | -5.34 M | -1.97 M | -2.55 M | - | -557 K | -1.08 M | -1.32 M | - | -6.02 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -557 K | -35.2 M | -11.5 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 62.59 | -0.37 % | $ 92.7 B | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.07 | 0.33 % | $ 1.63 B | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.59 | 1.2 % | $ 36.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.7 | 0.73 % | $ 347 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 81.19 | 0.17 % | $ 47.5 B | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.6 | 0.05 % | $ 122 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.13 | 0.49 % | $ 874 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 36.74 | -0.05 % | $ 5.47 K | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 32.64 | -5.23 % | $ 1.5 B | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.9 | 2.15 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.36 | 2.42 % | $ 169 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.0 | 1.66 % | $ 16.9 M | ||
|
IRadimed Corporation
IRMD
|
27.3 M | $ 95.66 | -0.59 % | $ 1.22 B | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 85.63 | -1.4 % | $ 2.97 B | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Align Technology
ALGN
|
753 M | $ 171.87 | 0.74 % | $ 12.9 B | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.94 | -0.75 % | $ 374 M | ||
|
LENSAR
LNSR
|
-21 M | $ 5.89 | -2.81 % | $ 70.4 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.38 | 0.11 % | $ 266 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.36 | 2.26 % | $ 55.3 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 86.28 | -0.4 % | $ 111 B | ||
|
MiMedx Group
MDXG
|
78.8 M | $ 3.88 | -1.02 % | $ 573 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.7 | 4.84 % | $ 29.3 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 11.77 | 2.08 % | $ 466 M | ||
|
PAVmed
PAVM
|
-21.7 M | $ 10.04 | 1.93 % | $ 6.73 M |